What is the Share Price of Aurobindo Pharma Ltd?
- Answer Field
-
The share price of Aurobindo Pharma Ltd for NSE is ₹ 1229.1 and for BSE is ₹ 1229.4.
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
AUROBINDO PHARMA LTD SHARE PRICE
Sector: Pharmaceuticals
19.50
(1.61%)
1D
Last updated: Apr 30 2025 03:30 PM
275
524804
AUROPHARMA
Compare to
View
Display
Studies
No Data Available
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
AUROBINDO PHARMA LTD performance
Open Price
₹ 1213.30
Prev. Close
₹ 1209.60
Volume (Shares)
1099985.00
Total traded value
₹ 13519.91
Upper Circuit
₹ 1330.50
Lower Circuit
₹ 1088.70
AUROBINDO PHARMA LTD Share Price Update
As of the latest trading session, AUROBINDO PHARMA LTD share price is currently at ₹ 1229.1, which is up by ₹ 19.50 from its previous closing. Today, the stock has fluctuated between ₹ 1212.00 and ₹ 1235.00. Over the past year, AUROBINDO PHARMA LTD has achieved a return of 6.55 %. In the last month alone, the return has been 8.37 %. Read More...
AUROBINDO PHARMA LTD fundamentals
-
Market cap (Cr)
72,017.71
-
P/E Ratio (TTM)
37.57
-
Beta
0.82
-
Book Value / share
335.47
-
Return on equity
10.35%
-
EPS (TTM)
32.72
-
Dividend yield
0.37%
-
Net profit/quarter (Cr)
472.05
-
Market cap (Cr)
72,035.30
-
P/E Ratio (TTM)
37.57
-
Beta
0.76
-
Book Value / share
335.47
-
Return on equity
10.35%
-
EPS (TTM)
32.72
-
Dividend yield
0.37%
-
Net profit/quarter (Cr)
472.05
AUROBINDO PHARMA LTD Financials
Key Results
Key Ratios
Balance sheet
Cash Flow
Competition
Revenue
Net income
| Particulars | DEC 2024 (Values in Cr) |
|---|---|
| Revenue | 2883.56 |
| Operating Expense | 2337.95 |
| Net Profit | 472.05 |
| Net Profit Margin (%) | 16.37 |
| Earnings Per Share (EPS) | 8.13 |
| EBITDA | 767.41 |
| Effective Tax Rate (%) | 25.41 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
|---|---|---|---|---|---|
| AMBALAL SARABHAI ENTERPRISES L | 36.46 | 19.60 | 1.99 | 279.41 | 34.11 / 77.70 |
| BLISS GVS PHARMA LTD | 119.00 | 15.60 | 1.24 | 1253.91 | 92.25 / 184.95 |
| CIPLA LTD | 1549.65 | 25.08 | 4.41 | 125155.99 | 1310.05 / 1702.00 |
| FERMENTA BIOTECH LIMITED | 260.70 | 21.60 | 2.64 | 767.27 | 145.00 / 449.00 |
| Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
|---|---|---|---|---|---|
| AMBALAL SARABHAI ENTERPRISES L | 36.46 | 21.96 | 6.19 | 279.41 | 34.11 / 77.70 |
| AMRUTAJAN HEALTH LTD | 692.80 | 40.61 | 6.72 | 2002.93 | 548.05 / 861.40 |
| ASTRAZENECA PHARMA IND LT | 8665.50 | 129.24 | 31.88 | 21663.75 | 5000.00 / 9199.00 |
| BLISS GVS PHARMA LTD | 119.00 | 15.45 | 1.22 | 1253.91 | 92.25 / 184.95 |
AUROBINDO PHARMA LTD Technicals Summary
- EMA & SMA
- Resistance and Support
- Delivery and Volume
- Beta
- Price Change Analysis
1229.10
1.61
2
Bearish
14
Bullish
- 5 Days 1223.60
- 26 Days 1175.30
- 10 Days 1207.40
- 50 Days 1168.10
- 12 Days 1201.20
- 100 Days 1193.60
- 20 Days 1183.30
- 200 Days 1213.40
1219.03
PIVOT
First Support
1193.97First Resistance
1234.67Second Support
1178.33Second Resistance
1259.73Third Support
1153.27Third Resistance
1275.37RSI
58.12ADX
12.28MACD
25.87Williams % R
-20.94Commodity Channel Index (CCI)
78.79Date
2025-04-30Week
442531.00Same Day
666865.00Month
632411.001 Year
0.823 Year
0.78Over 1 Month
8.37%
Over 1 Year
6.55%
Over 3 Months
3.88%
Over 3 Years
24.13%
Over 6 Months
-12.52%
Over 5 Years
14.45%
Aurobindo Pharma Share Result Highlights
Aurobindo Pharma reported Q2 revenue of ₹7,796 crore for this financial year, reflecting a YoY growth of 7.99%. Operating profit reached ₹1,566 crore with an OPM of 20%. Profit after tax stood at ₹817 crore, a YoY growth of 9%, despite a sequential dip from Q1 of this year. Over the last decade, compounded sales growth was 14%, and profit growth was 11%. Return on equity, over the same period was 16%.
Aurobindo Pharma Share Annual Reports
For FY24, Aurobindo Pharma achieved a 16.68% sales growth, reaching ₹29,002 crore compared to ₹24,859 crore in FY23. Net profit stood at ₹3,169 crore, highlighting moderate recovery despite lower profitability over recent years. EPS for the year was ₹54.15. The company’s 10-year compounded profit growth averaged 11%, but three-year growth remained stagnant at -1%. Return on equity, though stable, declined to 12% last year, reflecting the challenges in maintaining margins in a competitive sector. Aurobindo Pharma’s share price saw an increase of 19% in the last 1-year period.
Aurobindo Pharma Share Dividend
Aurobindo Pharma’s dividend payout declined to 8% in FY24, down from 23% in FY23, indicating a shift in financial priorities. The dividend yield for the year stood at a modest 0.37%. While the company’s long-term growth in sales and profits is robust, recent profit stagnation (-1% compounded growth over three years) and declining returns on equity have impacted dividend trends.
Additional FAQs
1. Who is the CEO of Aurobindo Pharma Ltd?
Mr. K. Nithyananda Reddy is the Vice Chairman and Managing Director of Aurobindo Pharma Ltd. He oversees the company’s operations and global pharmaceutical initiatives.
2. When was Aurobindo Pharma Ltd established?
Aurobindo Pharma Ltd was established in 1986 and has grown into a prominent pharmaceutical company with a significant presence in both domestic and international markets.
3. What factors influence the Aurobindo Pharma Share Price?
Aurobindo Pharma’s share price is influenced by factors such as regulatory approvals, the launch of new pharmaceutical products, revenue growth, and global market conditions for generics and APIs.
4. Is Aurobindo Pharma Ltd debt free?
No, Aurobindo Pharma Ltd is not debt free, as it utilises borrowings to support its manufacturing, research, and global expansion efforts.
5. What is the CAGR of Aurobindo Pharma Share?
The CAGR of Aurobindo Pharma’s share is 8% over 10 years, 22% over 5 years, and 22% over 3 years.
6. How has the Aurobindo Pharma Share Price performed over the past year?
Over the past year, Aurobindo Pharma’s share price has increased by 19%, reflecting improved business performance and market sentiment toward its pharmaceutical offerings.
AUROBINDO PHARMA LTD Share Price
Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company. Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it. APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations. The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products. APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities. Aurobindo Pharma has identified international operations also catering to over 150 countries.
The Company has accelerated the DMF/ANDA filings programme in its efforts to build a broad product portfolio for the regulated markets. Cumulatively, the Company has filed a total of 337 DMFs (Drug Master Files), of which 110 are with US FDA, and 133 in Europe including with the EDQM and 102 in other countries. This is one of the highest filings. The Company commenced its operations during the year 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry and it became a public venture in 1992. In the same year 1992, another unit was also set up for the manufacture of CMIC Chloride, a bulk drug intermediate at Pashamylaram, near Hyderabad through another company, namely Chaitanya Organics Pvt. Ltd. Later in 1994-95, it was merged with the company. The commercial production of the pharmaceutical formulation unit was started in April of the year 1994. Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. Glaxo (India), the Indian subsidiary of the UK-based multinational came to an alliance with the company to meet its global bulk drug requirements during the year 1997. In the year 1998, the company had launched new formulations like auronim Suspension in the paediatric segment.
During 1999-2000, the company diversified its product portfolio further with the introduction of wide range of Cephalosporins (Oral & Sterile) and anti - virals in addition to macrolides, anti-ulcerants, quinolones, semi-synthetic penicillins and formulations for domestic and export market. APL made Joint Ventures for formulations business in US, with an investment of a million in the year 2000. Sri Chakra Remedies Ltd was amalgamated with the company in the identical year of 2000. The Company has launched an exclusive anti-viral division Immune during the year 2001 to educate and to provide preventive drug care for HIV/AIDS patients in the country. APL had launched two more drugs in the same year of 2001, namely Efavirenz (Viranz) and Nelfinavir (NELVEX) for the treatment of AIDS. During the year 2001-02 the company acquired 79% stake in Ranit Pharma Company under the same management. Ranit Pharma and Calc Private Ltd were amalgamated with APL as at 1st April of the year 2002.
Citadel Aurobindo Biotech Ltd, a 50:50 Joint Venture (JV) Company introduced Aztreonam a Monabactam Betalactam antibiotic for the first time in the Indian Pharma Market with a brand name 'TREONAM' in the year 2003. During the same year the JV was happened between APL and Shanxi Tongling Pharmaceuticals Company, as an upshot formulated the JV Company under the name of Aurobindo Tongling (Datong) pharmaceuticals Ltd, China, for manufacture of pharmaceutical products to the local market. APL's 100% subsidiary company in China had commenced its commercial production during the year 2003-2004, which was formulated to procure raw material 6 APA at an economical cost. APL also launched the second JV Company in US for the purpose of Research and Development. During the year 2004, the company received its first Certificate of Suitability (CoS) approval from the European Directorate for Quality Medicines (EDQM) for its product in the therapeutic segment of gastroenterology.
During the year 2004-05 the company acquired a sterile plant of Dee Pharma for the consideration of Rs.38 million which located at Bhiwadi in Rajasthan. US FDA part of Department of health and human science approved the Unit VIII facility of the company in the year of 2005 as a site to manufacture of APIs for the US Market. Also in the same year APL had received US FDA clearance for AIDS drug. The State Labour Department of the Government of Andhra Pradesh has awarded the 'Best Management Award' for the year 2005 for the Company's contributions towards community development, harmonious employee relations and their welfare. During the year 2005-06, the company made a strategic entry with its generic formulations in the premium markets of USA & Europe, participated in the PEPFAR program initiated by the Government of USA and consolidated its strengths in the less regulated and emerging markets. Also in same year APL had acquired the UK based Milpharm Limited, the generic formulation pharmaceutical company engaged in marketing generic formulations mainly in the UK market. During March of the year 2007, the US FDA has granted final approval for the Company's Didanosine Oral Suspension (Pediatric Powder) 10 mg / ml. As at June 13th of the year 2007 the Company unveiled their new Logo and Corporate Identity at a ceremony in Hyderabad. The new corporate logo reflects this pace and leadership. Artistic lines intersect to make up the company's initials 'A' and 'P'. The way the initials 'A' and 'P' have joined conveys the spirit of 'partnership' with the company's business. The Hon'ble High Court of Andhra Pradesh has approved the scheme of arrangement for merger of APL Life Sciences and Senor Organics into the company and the utilisation of share premium account of the company during June of the year 2007.
APL concluded a strategic deal, for acquisition of intellectual property & marketing suthorizations, with TAD Italy, a generic company registered in Italy during March of the year 2008. This acquisition will give Aurobindo an access to more than 70 ready to market products, which will fast track Aurobindo's entry into the Italian generic market. As a part of this deal, APL also acquired high profile OTC brands - Mapooro and Carmiooro from TAD in same period of the year 2008.
On 6 September 2010, Aurobindo Pharma announced that it has entered into licensing and supply agreements with AstraZeneca, one of the world's leading biopharmaceutical companies, to supply several solid dosage and sterile products for emerging markets.
On 11 January 2011, Aurobindo Pharma announced that it had entered into a definitive agreement with China National Pharmaceutical Group Corporation (Sinopharm) to divest in its subsidiary company Aurobindo (Datong) Bio Pharma Co Ltd, China (ADBPL), subject to regulatory approvals. ADBPL is engaged in manufacturing of 6APA, a derivative of Penicillin-G. Aurobindo Pharma decided to retain 19.50% stake in ADBPL so as to ensure uninterrupted supply of raw materials at competitive price.
On 7 September 2011, Aurobindo Pharma announced the establishment of an equal joint venture in Russia with OJSC DIOD to manufacture and sell pharmaceuticals in Russia, Belarus and Kazakhstan.
On 1 April 2014, Aurobindo Pharma announced the completion of the acquisition of certain commercial operations in Western Europe from Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The agreement to acquire the Actavis operations was announced in January 2014.
On 5 December 2014, Aurobindo Pharma announced the completion of acquisition of assets of nutritional supplement maker, Natrol Inc. and other affiliate entities (Natrol) through its wholly owned subsidiary Aurobindo Pharma USA Inc. (APUSA). On 12 November 2014, APUSA emerged as the highest and best bidder to acquire assets of Natrol under the auction process by the United States Bankruptcy Court for the District of Delaware. APUSA acquired the manufacturing assets, personnel, commercial infrastructure including the well established nutraceuticals brands in USA of Natrol along with an agreement to take on certain liabilities, with a bid of $132.5 million.
On 25 November 2016, Arrow Generiques SAS, a French subsidiary of Aurobindo Pharma Ltd, announced the signing of an agreement to acquire the right, title and interest in its products Calcium and Calcium Vitamin D3 in France, including the use of the OROCAL trademark, from Teva Pharmaceutical Industries.
On 7 January 2017, Aurobindo Pharma announced the signing of a binding agreement by and through its wholly owned step-down subsidiary, Agile Pharma B.V, Netherlands, to acquire Generis Farmaceutica SA, a Portuguese pharmaceutical company, for a total consideration 135 million Euro, including net working capital of 21.7 million Euro.
On 9 February, 2017, Aurobindo Pharma announced the acquisition of four cell culture derived biosimilar products from TL Biopharmaceutical AG. As part of this agreement, TL will supply all the developmental data for four molecules and Aurobindo and/or its affiliates will develop, commercialize and market these products globally.
As on 31 March 2018,the company has 56 subsidiary companies under its roof.
During the FY2018,the company launched 38 products including 6 injectables in the US. As on 31 March 2018, the Company filed 478 ANDAs on a cumulative basis.
During the year 2018, Agile Pharma BV, a step down subsidiary of the Company acquired Generis Farmaceuita SA and its 4 subsidiaries viz. Mer Medicamentos, Portugal, Generis Phar, Portugal, Pharma APS, Portugal and Generis Mozambique, Portugal. Post acquisition of Generis Farmaceuita SA, Portugal, as part of restructuring of operations in Portugal, Aurobindo Pharma (Portugal) Unipessoal Limitada and Aurovitas, Unipessoal LDA, Mer Medicamentos, Lda, Farma APS and Generis Mozambique have been either merged with Generis Farmacutica SA or liquidated.
On May 28, 2019 the Board of Directors had accorded its approval for the draft scheme for merger of Company's 5 (Five) Wholly Owned Subsidiaries (i.e. APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited and APL Healthcare Limited) and 1 (one) step-down wholly owned subsidiary (i.e. Silicon Life Sciences Private Limited) with the Company. No shares of the Company will be issued as consideration for the said amalgamation and the shares held by the Company in its wholly owned subsidiaries and step-down wholly owned subsidiary shall stand cancelled. The Scheme would be subject to the requisite statutory/ regulatory approvals including the approval of the National Company Law Tribunal (Hyderabad Bench). Pursuant to the orders dated 30 September 2019, the required approvals of the Shareholders and unsecured creditors were obtained at the meetings held on 30 November 2019.
The Company has made an investment of Rs 150 million in Synergy Remedies Private Limited (Synergy), a Tirupathi based pharma company and acquired 19.9% holding in the said company. The objective of this acquisition was to ensure assured supplies of some of the APIs and intermediates.
During the FY2020,the Company through Auro Vaccines LLC, 100% subsidiary of Aurobindo Pharma USA Inc., USA, which in turn is 100% subsidiary of the Company, acquired certain R&D assets from Profectus BioSciences Inc'., USA, a clinicalstage vaccine development company in the design and development of preventive and therapeutic vaccines for an upfront cash consideration US$11.29 million with potential earn outs on achieving certain milestones. This acquisition provided access to Proprietary & Innovative technology platforms for Prophylactic use & Therapeutic use along with Global R&D center to develop newer vaccines from basic discovery research into FDA-approved product.
The Board of Aurobindo Pharma Limited on 3rd June 2020 had approved the transfer of Company's Biosimilar business and related R&D manufacturing facilities (Unit-17 and R&D-3) situated at survey No. 77 & 78, Indrakaran Village, Kandi Mandai, Sanga Reddy District, Telangana to its newly incorporated wholly owned subsidiary CuraTeQ Biologics Private Limited (CuraTeQ), through a slump sale.
On 25 October 2020, pursuant to the Board's approval, the Group entered into a definitive agreement to dispose of business assets of a wholly-owned step-down subsidiary, Natrol LLC, United States of America as a going concern with related assets, liabilities, products, brands and employees for a cash price of USD 550 million.
The Board in its meeting held on 16 October 2020 decided to enter into a share purchase agreement to acquire 100% equity share capital of MViyes Pharma Ventures Private Limited. MViyes Is holding 32.18% shareholding In Eugia Pharma Specialties Limited, a joint venture company In which the Parent Company, through its wholly-owned subsidiary company, is holding 67.82%. By this acquisition, both Eugia Pharma Specialities Limited and MViyes Pharma Ventures Private Limited have become wholly owned subsidiaries.
During the FY2021,the company has incorporated WYTELLS PHARMA PRIVATE LIMITED w.e.f 20 February 2021, as a subsidiary to Eugia Pharma Specialties Limited, India.
During the period 2021-22, Aurobindo Pharma Gmbh Germany merged with Puren Pharma GmbH w.e.f. October 1, 2021. CuraTeQ Biologics GmbH was Liquidated w.e.f. October 7, 2021 and Longxiang Pharma Taizhou Co. Ltd. was Liquidated w.e.f. August 31, 2021.
The Company has transferred 100% stake in Auro Cure Private Limited, a wholly-owned subsidiary of Company to Eugia Pharma Specialities Limited and consequently, Auro Cure Private Limited has become wholly owned step-down subsidiary of the Company. It transferred business undertaking comprised in Unit-16 of the Company, on a going concern basis, to Wytells Pharma Private
Limited, a wholly-owned step-down subsidiary of the Company. i.e. , Wytells Pharma Private Limited is a 100% subsidiary of Eugia
Pharma Specialities Limited which in turn is a wholly-owned subsidiary of the Company. It transferred vaccines business undertaking comprised in Unit-18, on a going concern basis, to Auro Vaccines Private Limited, a wholly-owned subsidiary of the Company; and also transferred equity shares of Tergene Biotech Private Limited, a subsidiary, to Auro Vaccines Private Limited, a wholly-owned subsidiary of the Company.
The Board of Directors of the Company at its meeting held on July 1, 2021, has approved the transfer of business undertaking comprised in Unit·4, on an on-going concern basis, to Eugia Pharma Specialities Limited, a wholly-owned subsidiary of the Company.
During the year 2022, Auro PR Inc, a subsidiary of Helix Healthcare B.V. Netherlands, acquired certain properties including rights, title and interest in the assets and liabilities owned by Mylan LLC USA. The Company acquired the business of Veritaz Healthcare Limited on slump sale basis for a consideration of Rs. 1,710 million on March 28, 2022, which operates in the pharmaceutical industry in India and sells branded generic formulations and other health care related products.
During the period 2022-23, Auro PR I LLC (formerly known as Mylan LLC) Merged with Auro PR Inc w.e.f. May 23, 2022. Theranym Biologics Private Limited was incorporated as wholly owned subsidiary of Curateq Biologics Private Limited w.e.f. September 22, 2022. PT Aurogen Pharma Indonesia was incorporated as a wholly owned stepdown subsidiary (99% held by Helix Healthcare BV and 1% held by Agile Pharma BV) w.e.f. July 1, 2022. 51% share capital of GLS Pharma Limited was acquired and it became a subsidiary with effect from August 17, 2022.
The Company launched 34 products in USA, including 17 injectable products in 2023. It completed treatment phase of trastuzumab, a biosimilar to Herceptin, in a Phase 3 study comprising 690 metastatic breast cancer patients during 2022-23. It acquired 51% stake in the domestic oncology business of GLS Pharma Limited.
Parent organization
Indian Private
NSE symbol
AUROPHARMA
Founded
1986
Board Of Directors
Kambam Nityananda Reddy
Vice Chairman & M.D.
M Madan Mohan Reddy
Whole-time Director
P V Ramprasad Reddy
Non Executive Director
Savita Mahajan
Independent Director
Girish Paman Vanvari
Independent Director
P Sarath Chandra Reddy
Non Executive Director
Santanu Mukherjee
Independent Director
Deepali Pant Joshi
Independent Director
M R Kumar
Chairman & Independent Directo
Satakarni Makkapati
Non Executive Director
Explore More Investment Options
Similar stocks
ONYX
57.1
2.59
BLUEJET
711.15
25.75
AMIORG
1130.6
40.29
ORTINGLOBE
10.85
0.32
GLAXO
2964.6
62.40
AMRUTANJAN
694.3
14.20
INDOCO
230.6
3.91
JBCHEPHARM
1612.4
26.90
SUNPHARMA
1832.3
26.80
LUPIN
2095.6
28.50
Frequently Asked Questions
What is the Market Cap of Aurobindo Pharma Ltd?
- Answer Field
-
The market cap of Aurobindo Pharma Ltd for NSE is ₹ 7,20,17.71 Cr. and for BSE is ₹ 7,20,35.30 Cr. as of now.
What is the 52 Week High and Low of Aurobindo Pharma Ltd?
- Answer Field
-
The 52 Week High and Low of Aurobindo Pharma Ltd for NSE is ₹ 1592.00 and ₹ 1010.00 and for BSE is ₹ 1592.55 and ₹ 994.35.
How to Buy Aurobindo Pharma Ltd share?
- Answer Field
-
You can trade in Aurobindo Pharma Ltd shares with Bajaj Broking by opening a Demat Account.
What is 1 year return for Aurobindo Pharma Ltd?
- Answer Field
-
The 1 year returns on the stock has been 6.55%.
What is the Current Share Price of Aurobindo Pharma Ltd?
- Answer Field
-
Aurobindo Pharma Ltd share price is for NSE ₹ 1229.1 & for BSE ₹ 1229.4 as on Apr 30 2025 03:30 PM.
What is the Market Cap of Aurobindo Pharma Ltd Share?
- Answer Field
-
The market cap of Aurobindo Pharma Ltd for NSE ₹ 7,20,17.71 & for BSE ₹ 7,20,35.30 as on Apr 30 2025 03:30 PM.
What is the P/E Ratio of Aurobindo Pharma Ltd Share?
- Answer Field
-
As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Aurobindo Pharma Ltd share is 37.57.
What is the PB ratio of Aurobindo Pharma Ltd Share?
- Answer Field
-
As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Aurobindo Pharma Ltd share is 335.47.
How to Buy Aurobindo Pharma Ltd Share?
- Answer Field
-
You can trade in Aurobindo Pharma Ltd shares with Bajaj Broking by opening a demat account.
How to Buy Aurobindo Pharma Ltd Share on Bajaj Broking App?
- Answer Field
-
To buy Aurobindo Pharma Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Aurobindo Pharma Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found
Realated News & Articles
+91
|
Please Enter Mobile Number
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
+91
|
Products
Calculator
Platforms
- footer content
Knowledge Centre
Important Links
Explore
Corporate
Discover Bajaj Broking
Follow Us
- footer content
-
TRENDING CALCULATORS AND STOCKS ON BAJAJ BROKING
TOOLS:
Popular Stock
- top-popular-on-bfsl
-
POPULAR STOCKS: Tata Motors Share Price Infosys Share Price IRFC Share Price SBI Card Share Price Cipla Share Price NBCC Share Price IDFC First Bank Share Price IRCTC Share Price PNB Share Price Vodafone Idea Share Price Axis Bank Share Price JSW Steel Share Price Bandhan Bank Share Price SBI Share Price Tata Steel Share Price ONGC Share Price Ashok Leyland Share Price Paytm Share Price Subex Share Price DLF Share Price Reliance Share Price HDFC Bank Share Price Suzlon Share Price IOC Share Price HUL Share Price Asian Paints Share Price Bank Of Baroda Share Price ITC Share Price TCS Share Price HFCL Share Price Icici Bank Share Price Tata Chemicals Share Price CDSI Share Price MRF Share Price Tata Power Share Price Adani Green share price BPCL Share Price Vedanta Share Price Dmart Share Price Hindalco Share Price LIC Share Price SAIL Share Price Adani Port Share Price IEX Share Price Nalco Share Price L&T Share Price Adani Power Share Price BHEL Share Price Bajaj Finance Share Price Canara Bank Share Price Indusind Bank Share Price Gail Share Price Yes Bank Share Price Wipro Share Price Happiest Minds Share Price Coal India Share Price Maruti Share Price Reliance Power Share Price
INDIAN INDICES: Nifty 50 Share Price SENSEX Share Price Nifty Next 50 Share Price BSE100 Share Price Nifty Bank Share Price LRGCAP Share Price Nifty 100 Share Price MIDCAP Share Price Nifty 200 Share Price SMLCAP Share Price Nifty 500 Share Price BSE500 Share Price Nifty Midcap 50 Share Price ALLCAP Share Price NIFTY SMLCAP 50 Share Price BSE200 Share Price India VIX Share Price BSEIPO Share Price